At the University of Kentucky (UK), we have established the Center for Clinical and Translational Science (CCTS) as a home for clinical and translational research. UK is located in Lexington, on the western edge of mid-Appalachia, one ofthe poorest areas ofthe country, where there are unprecedented disparities in disease and mortality. Many of these disparities stem from risky behaviors, such as smoking, drug abuse, and obesity. In this proposal, our overarching goal is to transform the pace, effectiveness, and quality of translational research at UK which will result in better health for the people of mid-Appalachia. Scientific discovery offers the potential for improved care, with community-based research offering a faster impact on health through a better dissemination of optimal medical care. However, scientific discoveries often do not reach the community due to the many difficulties with navigating the complex process of clinical and translational research. In this application, we will capitalize on our strengths in education, basic and clinical sciences, as well as our outstanding programs in practice- and community- based participatory research. These efforts will result in scientific discovery that will impact the health ofthe Appalachian rural community in the near term, and prime the pipeline for the future. To accomplish these goals, UK will form a collaboration with Marshall University, which is 2 hr away in Huntington, WV. In addition, we will form an Appalachian Translational Reseach Network involving not only Marshall, but also the CTSAs at the Ohio State University, University of Cinncinati, Morehead University, and Pikeville School of Osteopathic Medicine. This network will be especially important in the further development of our strong programs in community based participatory research. To help integrate our efforts, we have developed an innovative group of faculty CATalysts, who will build collaborative team science programs backed by generous pilot funding that will target novel ideas at all levels of science. New CCTS programs in """"""""Drug Development"""""""", """"""""Novel Methodologies"""""""", and """"""""Risk-Related Behavior Research"""""""" will capitalize on our strengths, engage investigators with diverse areas of expertise, and will more quickly impact the health of the Appalachian community. We have recently recruited a new leader in Biomedical Informatics and have invested heavily in this program, which will greatly improve our ability to transform data into knowledge throughout the CCTS. Through these initiatives, UK will fulfill its mandate as Kentucky's flagship university to improve the health of Central Appalachia, and thereby add unique value to improvements in the health ofthe nation.

Public Health Relevance

The CCTS at UK has developed well-integrated relationships with University programs in Central Appalachia and with rural health programs. We routinely apply a foundation principal of community based participatory research, where the lay community identifies ttie research issues and co-develops solutions. This proposal seeks to make research more relevant by breaking down bamers to research translation and greatly improving the pace by which science discoveries drive improvements in health in Kentucky and the nation.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1TR000117-04
Application #
8637116
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Brazhnik, Olga
Project Start
2011-06-01
Project End
2016-02-29
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
4
Fiscal Year
2014
Total Cost
$3,355,995
Indirect Cost
$1,037,821
Name
University of Kentucky
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Rotroff, Daniel M; Pijut, Sonja S; Marvel, Skylar W et al. (2018) Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. Clin Pharmacol Ther 103:712-721
Ebersole, J L; Dawson 3rd, D A; Emecen Huja, P et al. (2018) Age and Periodontal Health - Immunological View. Curr Oral Health Rep 5:229-241
Ferrin, John; Kirakodu, Sreenatha; Jensen, David et al. (2018) Gene expression analysis of neuropeptides in oral mucosa during periodontal disease in non-human primates. J Periodontol 89:858-866
Lee, Jennifer; Yanckello, Lucille M; Ma, David et al. (2018) Neuroimaging Biomarkers of mTOR Inhibition on Vascular and Metabolic Functions in Aging Brain and Alzheimer's Disease. Front Aging Neurosci 10:225
Knudsen, Hannah K; Lofwall, Michelle R; Walsh, Sharon L et al. (2018) Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers. J Addict Med 12:31-39
Klyachkin, Yuri M; Idris, Amr; Rodell, Christopher B et al. (2018) Cathelicidin Related Antimicrobial Peptide (CRAMP) Enhances Bone Marrow Cell Retention and Attenuates Cardiac Dysfunction in a Mouse Model of Myocardial Infarction. Stem Cell Rev 14:702-714
Snell-Rood, Claire; Carpenter-Song, Elizabeth (2018) Depression in a depressed area: Deservingness, mental illness, and treatment in the contemporary rural U.S. Soc Sci Med 219:78-86
Cui, Zheng; Wang, Xia-Chang; Liu, Xiaodong et al. (2018) Self-Resistance during Muraymycin Biosynthesis: a Complementary Nucleotidyltransferase and Phosphotransferase with Identical Modification Sites and Distinct Temporal Order. Antimicrob Agents Chemother 62:
Knudsen, Hannah K; Studts, Jamie L (2018) Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment. J Behav Health Serv Res :
Evans, Joyce M; Knapp, Charles F; Goswami, Nandu (2018) Artificial Gravity as a Countermeasure to the Cardiovascular Deconditioning of Spaceflight: Gender Perspectives. Front Physiol 9:716

Showing the most recent 10 out of 735 publications